Alembic Accounts Payable vs Total Liab Analysis

APLLTD Stock

1,081 7.20 0.66%

Alembic Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alembic Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alembic Pharmaceuticals is a good investment. Please check the relationship between Alembic Pharmaceuticals Accounts Payable and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alembic Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alembic Pharmaceuticals Accounts Payable account and Total Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Alembic Pharmaceuticals' Accounts Payable and Total Liab is 0.59. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Liab in the same time period over historical financial statements of Alembic Pharmaceuticals Limited, assuming nothing else is changed. The correlation between historical values of Alembic Pharmaceuticals' Accounts Payable and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Alembic Pharmaceuticals Limited are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Accounts Payable i.e., Alembic Pharmaceuticals' Accounts Payable and Total Liab go up and down completely randomly.

Correlation Coefficient

0.59

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Alembic Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Alembic Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Alembic Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alembic Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alembic Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

As of November 29, 2024, Selling General Administrative is expected to decline to about 1.4 B. In addition to that, Tax Provision is expected to decline to about 152 M

	2021	2022	2023	2024 (projected)
Interest Expense	177.3M	501.7M	561.9M	590.0M
Depreciation And Amortization	2.9B	2.8B	2.7B	2.9B

Interest Expense Depreciation And Amortization

Alembic Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Retained Earnings	Accounts Payable	Short Term Debt	Net Receivables	Other Liab	Net Tangible Assets
Total Assets		0.64	0.27	0.95	0.98	0.99	0.59	0.11	0.99	0.14	0.25	0.49	0.4	0.99	-0.04	0.07	0.86	0.98	0.51	-0.06	0.76	0.77	0.8	0.78	0.85	0.86
Short Long Term Debt Total	0.64		0.13	0.78	0.48	0.65	0.97	-0.05	0.67	-0.09	-0.02	0.04	0.9	0.54	-0.31	-0.62	0.93	0.58	0.04	-0.03	0.31	0.45	0.89	0.72	0.38	0.38
Other Current Liab	0.27	0.13		0.2	0.25	0.27	0.16	-0.15	0.27	0.14	-0.07	0.15	0.28	0.22	0.19	0.38	0.26	0.26	0.16	-0.53	0.13	0.12	-0.02	0.19	0.19	0.22
Total Current Liabilities	0.95	0.78	0.2		0.88	0.94	0.72	0.13	0.94	0.14	0.19	0.39	0.5	0.91	-0.16	-0.16	0.94	0.94	0.4	0.02	0.7	0.68	0.91	0.86	0.78	0.77
Total Stockholder Equity	0.98	0.48	0.25	0.88		0.97	0.44	0.11	0.97	0.17	0.28	0.55	0.23	0.99	0.05	0.23	0.75	0.97	0.58	-0.07	0.79	0.78	0.69	0.69	0.86	0.89
Property Plant And Equipment Net	0.99	0.65	0.27	0.94	0.97		0.62	0.05	1.0	0.1	0.21	0.45	0.41	0.97	0.0	0.08	0.86	0.96	0.47	-0.05	0.73	0.77	0.8	0.73	0.81	0.84
Net Debt	0.59	0.97	0.16	0.72	0.44	0.62		-0.27	0.63	-0.04	-0.23	0.04	0.88	0.49	-0.16	-0.6	0.88	0.52	0.04	-0.14	0.29	0.47	0.85	0.67	0.27	0.34
Cash	0.11	-0.05	-0.15	0.13	0.11	0.05	-0.27		0.06	-0.17	0.92	0.02	-0.05	0.1	-0.62	0.03	0.08	0.18	0.01	0.48	0.03	-0.16	0.0	0.11	0.4	0.08
Non Current Assets Total	0.99	0.67	0.27	0.94	0.97	1.0	0.63	0.06		0.1	0.23	0.43	0.43	0.97	-0.01	0.06	0.87	0.95	0.46	-0.03	0.72	0.76	0.8	0.73	0.81	0.83
Non Currrent Assets Other	0.14	-0.09	0.14	0.14	0.17	0.1	-0.04	-0.17	0.1		-0.23	0.78	-0.18	0.21	0.12	0.05	0.04	0.21	0.76	-0.4	0.62	0.32	0.05	0.28	0.28	0.49
Cash And Short Term Investments	0.25	-0.02	-0.07	0.19	0.28	0.21	-0.23	0.92	0.23	-0.23		0.03	-0.01	0.24	-0.4	0.18	0.14	0.29	0.05	0.43	0.12	-0.01	-0.01	0.04	0.46	0.21
Common Stock Shares Outstanding	0.49	0.04	0.15	0.39	0.55	0.45	0.04	0.02	0.43	0.78	0.03		-0.13	0.59	0.08	0.17	0.24	0.57	1.0	-0.48	0.83	0.67	0.26	0.48	0.57	0.76
Non Current Liabilities Total	0.4	0.9	0.28	0.5	0.23	0.41	0.88	-0.05	0.43	-0.18	-0.01	-0.13		0.26	-0.37	-0.61	0.76	0.32	-0.13	-0.11	0.05	0.21	0.6	0.51	0.18	0.13
Inventory	0.99	0.54	0.22	0.91	0.99	0.97	0.49	0.1	0.97	0.21	0.24	0.59	0.26		0.0	0.14	0.78	0.99	0.61	-0.09	0.82	0.81	0.75	0.76	0.87	0.9
Other Current Assets	-0.04	-0.31	0.19	-0.16	0.05	0.0	-0.16	-0.62	-0.01	0.12	-0.4	0.08	-0.37	0.0		0.4	-0.27	-0.1	0.1	-0.28	0.07	0.13	-0.21	-0.42	-0.36	0.03
Other Stockholder Equity	0.07	-0.62	0.38	-0.16	0.23	0.08	-0.6	0.03	0.06	0.05	0.18	0.17	-0.61	0.14	0.4		-0.36	0.09	0.2	-0.19	0.15	0.14	-0.44	-0.26	0.22	0.23
Total Liab	0.86	0.93	0.26	0.94	0.75	0.86	0.88	0.08	0.87	0.04	0.14	0.24	0.76	0.78	-0.27	-0.36		0.83	0.25	-0.03	0.54	0.59	0.91	0.84	0.65	0.62
Total Current Assets	0.98	0.58	0.26	0.94	0.97	0.96	0.52	0.18	0.95	0.21	0.29	0.57	0.32	0.99	-0.1	0.09	0.83		0.59	-0.1	0.81	0.77	0.77	0.83	0.9	0.88
Common Stock	0.51	0.04	0.16	0.4	0.58	0.47	0.04	0.01	0.46	0.76	0.05	1.0	-0.13	0.61	0.1	0.2	0.25	0.59		-0.48	0.84	0.69	0.26	0.46	0.58	0.78
Current Deferred Revenue	-0.06	-0.03	-0.53	0.02	-0.07	-0.05	-0.14	0.48	-0.03	-0.4	0.43	-0.48	-0.11	-0.09	-0.28	-0.19	-0.03	-0.1	-0.48		-0.33	-0.49	0.02	-0.18	0.0	-0.29
Retained Earnings	0.76	0.31	0.13	0.7	0.79	0.73	0.29	0.03	0.72	0.62	0.12	0.83	0.05	0.82	0.07	0.15	0.54	0.81	0.84	-0.33		0.85	0.57	0.67	0.74	0.97
Accounts Payable	0.77	0.45	0.12	0.68	0.78	0.77	0.47	-0.16	0.76	0.32	-0.01	0.67	0.21	0.81	0.13	0.14	0.59	0.77	0.69	-0.49	0.85		0.64	0.62	0.63	0.89
Short Term Debt	0.8	0.89	-0.02	0.91	0.69	0.8	0.85	0.0	0.8	0.05	-0.01	0.26	0.6	0.75	-0.21	-0.44	0.91	0.77	0.26	0.02	0.57	0.64		0.83	0.56	0.61
Net Receivables	0.78	0.72	0.19	0.86	0.69	0.73	0.67	0.11	0.73	0.28	0.04	0.48	0.51	0.76	-0.42	-0.26	0.84	0.83	0.46	-0.18	0.67	0.62	0.83		0.77	0.67
Other Liab	0.85	0.38	0.19	0.78	0.86	0.81	0.27	0.4	0.81	0.28	0.46	0.57	0.18	0.87	-0.36	0.22	0.65	0.9	0.58	0.0	0.74	0.63	0.56	0.77		0.82
Net Tangible Assets	0.86	0.38	0.22	0.77	0.89	0.84	0.34	0.08	0.83	0.49	0.21	0.76	0.13	0.9	0.03	0.23	0.62	0.88	0.78	-0.29	0.97	0.89	0.61	0.67	0.82

Click cells to compare fundamentals

Alembic Pharmaceuticals Account Relationship Matchups

Alembic Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	59.9B	67.1B	71.2B	61.8B	64.5B	40.9B
Short Long Term Debt Total	18.3B	5.8B	7.2B	7.2B	5.1B	5.9B
Other Current Liab	418.9M	2.7B	3.0B	855.4M	2.7B	1.8B
Total Current Liabilities	17.5B	12.8B	17.2B	16.4B	14.6B	11.2B
Total Stockholder Equity	32.2B	51.3B	52.4B	43.7B	48.2B	26.7B
Property Plant And Equipment Net	31.0B	36.5B	39.5B	30.0B	30.7B	19.7B
Net Debt	17.6B	4.9B	6.6B	6.5B	3.9B	4.8B
Cash	718.4M	980.6M	610.9M	754.8M	1.2B	1.1B
Non Current Assets Total	35.3B	41.3B	42.6B	32.7B	33.7B	22.1B
Cash And Short Term Investments	718.4M	2.9B	610.9M	921.2M	1.2B	1.3B
Liabilities And Stockholders Equity	59.9B	67.1B	71.2B	61.8B	64.5B	40.9B
Non Current Liabilities Total	10.5B	3.6B	1.7B	1.8B	1.7B	3.2B
Inventory	11.9B	14.9B	16.1B	14.8B	16.4B	9.2B
Other Current Assets	200K	5.3B	3.8B	3.1B	2.9B	2.2B
Other Stockholder Equity	(31.1B)	27.0B	26.4B	7.5B	7.5B	5.6B
Total Liab	28.0B	16.4B	18.8B	18.1B	16.3B	14.3B
Total Current Assets	24.6B	25.8B	28.6B	29.1B	30.8B	18.9B
Accumulated Other Comprehensive Income	(5.0B)	18.5B	18.8B	335.4M	32.4M	30.8M
Current Deferred Revenue	2.1B	3.0B	3.7B	2.2B	(322.4M)	(306.3M)
Retained Earnings	15.4B	24.2B	25.5B	35.7B	40.3B	42.3B
Accounts Payable	6.3B	6.7B	7.1B	6.8B	7.4B	7.7B
Short Term Debt	8.7B	3.1B	6.4B	6.5B	4.5B	3.9B
Net Receivables	12.0B	3.5B	8.1B	10.5B	10.2B	7.0B
Other Liab	708M	867.1M	897.4M	958.1M	1.1B	847.2M
Net Tangible Assets	24.5B	29.2B	48.0B	50.8B	58.5B	61.4B
Other Assets	(1.7M)	1.1B	1.1B	1.2B	1.4B	1.5B
Short Long Term Debt	8.6B	200K	6.3B	6.4B	4.3B	3.8B
Property Plant Equipment	31.0B	36.5B	39.5B	30.0B	34.5B	23.0B
Long Term Debt Total	8.9B	2.7B	721.4M	692.3M	623.1M	591.9M
Intangible Assets	1.6B	2.7B	3.0B	3.2B	1.5B	0.0
Net Invested Capital	49.7B	53.3B	58.7B	50.1B	52.5B	52.2B
Net Working Capital	7.1B	13.0B	10.6B	12.7B	16.2B	11.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in Alembic Stock

Balance Sheet is a snapshot of the financial position of Alembic Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Alembic Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Alembic Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Alembic currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alembic Accounts Payable vs Total Liab Analysis

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

Correlation Coefficient

Accounts Payable

Total Liab

Alembic Pharmaceuticals fundamental ratios Correlations

Alembic Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alembic Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Alembic Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Shares Outstanding
Property Plant And Equipment Net	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Inventory	+ 0.99	Total Assets
Inventory	+ 0.99	Total Stockholder Equity

Other Current Assets	- 0.62	Cash
Other Stockholder Equity	- 0.62	Short Long Term Debt Total
Other Stockholder Equity	- 0.61	Non Current Liabilities Total
Other Stockholder Equity	- 0.6	Net Debt
Current Deferred Revenue	- 0.53	Other Current Liab
Accounts Payable	- 0.49	Current Deferred Revenue